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OBJECTIVES: Aspirin is recommended for prevention of myocardial infarction (MI) 
in elderly with type 2 diabetes although the beneﬁ ts of aspirin therapy have not been 
well established in this population. We evaluated the association between aspirin use 
and myocardial infarction (MI) among elderly newly treated with oral antidiabetes 
drugs, according to whether or not they had prior history of cardiovascular disease. 
METHODS: Using Quebec administrative databases, we conducted two nested case-
control analyses within a population-based cohort of 39,680 individuals aged 66 
years, newly treated with an antidiabetes drug, who had not used aspirin, antiplatelet 
or anticoagulant drugs and had no MI in the year before cohort entry. In the ﬁ rst 
analysis, eligible individuals had no previous cardiovascular disease recorded in the 
database, whereas in the second analysis, eligible individuals had a known cardiovas-
cular disease. Cases were patients who had a MI. For each case, we selected ﬁ ve 
controls matched for age, year of cohort entry and sex using incidence density sam-
pling. Exposure to aspirin was deﬁ ned as current, past or none. Odds ratios (OR) of 
MI were calculated using paired multivariate conditional logistic regression. RESULTS: 
We identiﬁ ed 1101 cases of MI among the cardiovascular disease-free individuals. 
Neither current [OR = 1.03 (95% CI: 0.82–1.28)] nor past users [0.95 (0.74–1.24)] 
of aspirin had a signiﬁ cant different risk of MI than non users. There were 770 cases 
of MI among those individuals with a prior history of cardiovascular disease. Com-
pared with non users of aspirin, both past [1.72 (1.30–2.28)] and current users [1.33 
(1.03–1.71)] had a signiﬁ cant higher risk of MI. CONCLUSIONS: These results 
suggest that aspirin does not provide a cardiovascular protection to elderly individuals 
with type 2 diabetes.
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OBJECTIVES: To identify the equivalent hypolipidemic doses of rosuvastatin com-
pared to atorvastatin and simvastatin. METHODS: A systematic review of clinical 
trials was conducted. The percentage reduction of baseline LDL cholesterol was used 
as a measure of clinical effectiveness. The weighted mean difference (WMD) of effec-
tiveness between comparators and rosuvastatin (separately) was calculated using the 
meta-regression approach, with logarithm of dosage ratio as an explanatory variable. 
Due to the heterogeneous baseline levels of cholesterol, the random effects model was 
used. As several observations came from single trials (various dosages of a given drug) 
a correlation of error terms may result. In a simpliﬁ ed, benchmark analysis no correla-
tions were assumed. In a full analysis it was assumed that: for two observations from 
a single trial regarding different patients the covariance equals the common variance 
of random-effects model; for two observations from a single trial with one group of 
patients in common the covariance is further increased by the variance of the effect 
for the shared group. Monte Carlo approach and Cholesky decomposition were used 
to calculate conﬁ dence intervals of equivalent dosage ratios taking into account the 
correlation of model estimates. RESULTS: In total 41 trials were found and used, 
allowing for 78 single comparisons of rosuvastatin with atorvastatin, and 25 with 
simvastatin. Dosage ratios of comparator to rosuvastatin used in the meta-regression 
amounted to 1:1, 2:1, 4:1, and 8:1. The full analysis yielded WMD = −8.64 + 
7.2*ln(dosage ratio) for atorvastatin and WMD = −15.94 + 7.55*ln(dosage ratio) for 
simvastatin. Benchmark analysis gave similar results. Resulting equivalence ratios 
amount to 3.32 for atorvastatin (95%CI: 2.93–3.79), and 8.26 (95%CI: 6.86–10.28) 
for simvastatin. CONCLUSIONS: Meta-regression approach allows for equivalence 
dosage analysis. Correlation issues need to be addressed for multiple treatment arms 
in a single study. Rosuvastatin yields equivalent hypolipemic effect for lower dosages 
than atorvastatin and simvastatin.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is progressive and fatal. Hemo-
dynamic parameters, physical functioning (PF), and health-related quality of life 
(HRQoL) worsen without treatment. The objective was to evaluate the distribution 
of changes in exercise capacity, hemodynamic parameters, and HRQoL in PAH 
patients treated with sitaxentan. Because cumulative distribution functions (CDFs) 
characterize treatment effects beyond conventional statistical signiﬁ cance (which is 
achievable in large studies with small changes that lack clinical meaning), this method 
was employed. METHODS: Adult PAH patients (n = 178) received 12 weeks of ran-
domized, double-blind treatment with placebo (n = 60) or sitaxentan 100 (n = 55) or 
300 (n = 63) mg once daily. The primary outcome measure was change in percent of 
predicted peak VO2 (PVO2); 6-minute walk distance (6MWD) measured exercise capac-
ity. Hemodynamic assessments included pulmonary and systemic vascular resistance 
(PVR and SVR, respectively), pulmonary capillary wedge pressure (PCWP), and cardiac 
index (CI). The Short Form-36 (SF-36) assessed HRQoL, including the PF domain. CDFs 
plotted the cumulative percentage of patients against percentage (and, separately, 
numeric) changes from baseline to week 12 in outcome measures. Kolmogorov-Smirnov 
tests assessed differences in separation between CDFs for sitaxentan and placebo. 
RESULTS: Signiﬁ cant differences between CDFs were observed for sitaxentan 300 mg 
(but not 100 mg) vs. placebo for both numeric and percentage change in percent of 
predicted PVO2 (P = 0.03). Signiﬁ cant differences occurred for sitaxsentan 100 and 
300 mg vs. placebo for 6MWD, PVR, SVR, and CI (P < 0.02 for each); the PCWP 
difference was signiﬁ cant only for percentage change at the 100-mg sitaxentan dose. 
No differences occurred for the SF-36 PF domain. CONCLUSIONS: Using CDF 
analysis incorporating the entire distribution of responses, sitaxentan signiﬁ cantly 
improved percent of predicted PVO2 (by numeric and percentage changes, 300-mg 
dose), 6MWD, PVR, SVR, CI, and PCWP (by percentage change, 100-mg dose), but 
not the SF-36 PF domain in PAH patients.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is an ultimately fatal condition 
that may worsen hemodynamic parameters and contribute to diminished physical 
functioning and health-related quality of life (HRQoL). Although these relationships 
are well described in adults with PAH, they are not fully characterized in pediatric 
populations. METHODS: Children (aged 1–17 years) with PAH received 16 weeks 
of randomized, double-blind treatment with sildenaﬁ l citrate or placebo. The primary 
outcome measure, peak VO2 (PVO2), assessed cardiopulmonary exercise capacity in 
children developmentally capable of exercise. Secondary measures (for all patients) 
included mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance 
index (PVRI), cardiac index (CI), and the Child Health Questionnaire-Parent Form 
(CHQ). Cumulative distribution functions (CDFs) plotted the cumulative percentage 
of patients against percentage changes (and also numeric changes) from baseline to 
week 16 in outcome measures. RESULTS: Of 234 randomized and treated children, 
106 were developmentally able to exercise; 148 to 221 provided non-exercise endpoint 
data. Descriptive separation between CDFs was evident for sildenaﬁ l versus placebo 
for percentage changes in PVO2, mPAP, PVRI, and CI. For example, 58 of 77 (75%) 
sildenaﬁ l-treated children had increases in the percentage change in PVO2 versus 13 
of 29 (45%) placebo-treated children. Descriptive separation between CDFs was not 
evident for CHQ domains of physical function, bodily pain, behavior, general health, 
and parental impact-time. Across all measures, an identical pattern of response proﬁ les 
was obtained when numeric (rather than percentage) changes were assessed. CON-
CLUSIONS: Cumulative distribution functions, which incorporate the entire distribu-
tion of responses, can enhance clinical interpretation of outcome measures. The 
distribution of responses on PVO2, mPAP, PVRI, and CI for sildenaﬁ l was descriptively 
more favorable compared with placebo, suggesting that sildenaﬁ l improves exercise 
capacity and hemodynamic function in children with PAH. Further research should 
elucidate the impact of disease and treatment on HRQoL in pediatric PAH.
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OBJECTIVES: Dyslipidemias involving elevated low-density lipoprotein cholesterol 
(LDL-C), low high-density lipoprotein cholesterol (HDL-C), and/or high triglycerides 
are correlates of cardiovascular disease (CVD). The degree to which risk persists after 
lipid modifying therapy (LMT), and varies between high risk populations, has not 
been well explored. We compare the prevalence of dyslipidemias§ before and after 
LMT among high CVD risk patients in clinical practice. METHODS: This is a pooled 
analysis of four observational, longitudinal, studies (PRIMULA) of primary care 
patients in Canada, Spain, Sweden, and the United Kingdom, ≥35 years old who initi-
ated LMT and continued therapy for >12 months. Data are reported for a total of 
12,768 high cardiovascular risk patients, more than half of whom had diabetes mel-
litus (DM), nearly a third with a history of CVD, and the remainder with a 10-year 
Framingham risk score (FRS) >20%. RESULTS: The majority (>95%) received statin 
monotherapy as their initial LMT. At baseline, those with a history of CVD had the 
lowest, and those with FRS > 20% the greatest prevalence of elevated LDL-C, elevated 
TG, low HDL-C and elevated LDL-C coupled with low HDL-C and/or elevated TG. 
After 12 months of follow-up, all high risk groups demonstrated improved lipid 
proﬁ les, though only among those with FRS > 20% did HDL-C improve. Persistent 
dyslipidemia was most rampant among those with a FRS > 20% and least among 
